Skip to main content
Erschienen in:

21.10.2020 | Thoracic Oncology

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer

verfasst von: Taichi Matsubara, MD, PhD, Shinkichi Takamori, MD, PhD, Naoki Haratake, MD, PhD, Takatoshi Fujishita, MD, PhD, Ryo Toyozawa, MD, Kensaku Ito, MD, PhD, Mototsugu Shimokawa, MD, PhD, Masafumi Yamaguchi, MD, PhD, Takashi Seto, MD, PhD, Tatsuro Okamoto, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Three immune-nutritional parameters exist for malignant tumors using serum C-reactive protein (CRP) and albumin: the Glasgow prognostic score (GPS), the modified GPS (mGPS), and the CRP-albumin ratio (CAR). However, it remains unclear which of the three parameters is the most predictive of prognosis. Therefore, this study compared the clinical and prognostic significance of these parameters for non-small cell carcinoma (NSCLC).

Methods

The study retrospectively enrolled 596 NSCLC patients who underwent surgical resection at the authors’ institution from January 2010 to December 2015 and investigated the clinicopathologic significance of GPS, mGPS, and CAR. The optimal cutoff value for CAR was determined by a receiver operating curve (ROC).

Results

The median age of the patients was 69 years. Lymph node metastases were identified in 99 patients, and 455 patients had a diagnosis of stage 1 disease. The positivity for GPS was 7.6%, and that of mGPS (score, 1 or 2) was 12.2%. Of the 596 patients, 480 patients (80.5%) were classified in the high CAR group. In univariate survival analyses, all three parameters were associated significantly with postoperative survival. The multivariate analyses showed CAR to be an independent prognostic factor. Additionally, survival analyses of the stage 1 subgroup were performed because CAR was higher for patients with an advanced stage of disease or lymph node metastases. In these subgroup analyses, CAR also was an independent prognostic factor.

Conclusion

As the most prognostic index, CAR may be useful among the immunonutritional parameters using CRP and albumin for resected NSCLC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2.
Zurück zum Zitat Williams BA, Sugimura H, Endo C, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 2006;81:1021–7.PubMedCrossRef Williams BA, Sugimura H, Endo C, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 2006;81:1021–7.PubMedCrossRef
3.
Zurück zum Zitat Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409–17. (discussioin 417–408) Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409–17. (discussioin 417–408)
4.
Zurück zum Zitat Sonobe M, Yamada T, Sato M, et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol. 2014;21:2546–54.PubMedCrossRef Sonobe M, Yamada T, Sato M, et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol. 2014;21:2546–54.PubMedCrossRef
5.
Zurück zum Zitat Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93:1813–20. (discussion 1820–1811) Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93:1813–20. (discussion 1820–1811)
6.
Zurück zum Zitat Mizuno T, Arimura T, Kuroda H, Sakakura N, Yatabe Y, Sakao Y. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. J Thorac Dis. 2018;10:1788–96.PubMedPubMedCentralCrossRef Mizuno T, Arimura T, Kuroda H, Sakakura N, Yatabe Y, Sakao Y. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. J Thorac Dis. 2018;10:1788–96.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Matsubara T, Takada K, Azuma K, et al. A clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol. 2019;26:1925–33.PubMedCrossRef Matsubara T, Takada K, Azuma K, et al. A clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol. 2019;26:1925–33.PubMedCrossRef
8.
Zurück zum Zitat Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRef Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRef
9.
Zurück zum Zitat Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRef Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRef
10.
Zurück zum Zitat Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small cell lung cancer. Br J Cancer. 2004;90:1704–6.PubMedPubMedCentralCrossRef Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small cell lung cancer. Br J Cancer. 2004;90:1704–6.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Inoue Y, Iwata T, Okugawa Y, et al. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology. 2013;84:100–7.PubMedCrossRef Inoue Y, Iwata T, Okugawa Y, et al. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology. 2013;84:100–7.PubMedCrossRef
12.
Zurück zum Zitat Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small cell lung cancer in elderly patients. Surg Today. 2017;47:836–43.PubMedCrossRef Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small cell lung cancer in elderly patients. Surg Today. 2017;47:836–43.PubMedCrossRef
13.
Zurück zum Zitat Zhang F, Ying L, Jin J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget. 2017;8:8835–42.PubMedCrossRef Zhang F, Ying L, Jin J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget. 2017;8:8835–42.PubMedCrossRef
14.
Zurück zum Zitat Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803–10.PubMedCrossRef Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803–10.PubMedCrossRef
15.
Zurück zum Zitat Yamauchi Y, Safi S, Muley T, et al. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients. Lung Cancer. 2017;114:62–7.PubMedCrossRef Yamauchi Y, Safi S, Muley T, et al. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients. Lung Cancer. 2017;114:62–7.PubMedCrossRef
16.
Zurück zum Zitat Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small cell lung cancer. Asia-Pacific J Clin Oncol. 2018;14:402–9.CrossRef Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small cell lung cancer. Asia-Pacific J Clin Oncol. 2018;14:402–9.CrossRef
18.
Zurück zum Zitat Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.PubMedCrossRef Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.PubMedCrossRef
19.
Zurück zum Zitat Murata M. Inflammation and cancer. Environment Health Prevent Med. 2018;23:50.CrossRef Murata M. Inflammation and cancer. Environment Health Prevent Med. 2018;23:50.CrossRef
20.
Zurück zum Zitat Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses, and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39:89–96.PubMedCrossRef Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses, and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39:89–96.PubMedCrossRef
21.
Zurück zum Zitat Yeung YT, Aziz F, Guerrero-Castilla A, Arguelles S. Signaling pathways in inflammation and anti-inflammatory therapies. Curr Pharmaceut Design. 2018;24:1449–84.CrossRef Yeung YT, Aziz F, Guerrero-Castilla A, Arguelles S. Signaling pathways in inflammation and anti-inflammatory therapies. Curr Pharmaceut Design. 2018;24:1449–84.CrossRef
22.
Zurück zum Zitat Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–97.PubMedCrossRef Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–97.PubMedCrossRef
23.
Zurück zum Zitat Lee JG, Cho BC, Bae MK, et al. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 2009;63:106–10.PubMedCrossRef Lee JG, Cho BC, Bae MK, et al. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 2009;63:106–10.PubMedCrossRef
24.
25.
Zurück zum Zitat O’Loughlin J, Lambert M, Karp I, et al. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tobacco Res. 2008;10:525–32.CrossRef O’Loughlin J, Lambert M, Karp I, et al. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tobacco Res. 2008;10:525–32.CrossRef
26.
Zurück zum Zitat Higgins ST, Kurti AN, Redner R, et al. A literature review on prevalence of gender differences and intersections with other vulnerabilities to tobacco use in the United States, 2004–2014. Prevent Med. 2015;80:89–100.CrossRef Higgins ST, Kurti AN, Redner R, et al. A literature review on prevalence of gender differences and intersections with other vulnerabilities to tobacco use in the United States, 2004–2014. Prevent Med. 2015;80:89–100.CrossRef
27.
28.
Zurück zum Zitat Wang L, Cao L, Wang H, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3-signaling pathway. Oncotarget. 2017;8:76116–28.PubMedPubMedCentralCrossRef Wang L, Cao L, Wang H, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3-signaling pathway. Oncotarget. 2017;8:76116–28.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Matsubara T, Tagawa T, Takada K, et al. Clinical and prognostic significance of the epithelial-mesenchymal transition in stage IA lung adenocarcinoma: a propensity score-matched analysis. Clin Lung Cancer. 2019;20(4):e504–13. Matsubara T, Tagawa T, Takada K, et al. Clinical and prognostic significance of the epithelial-mesenchymal transition in stage IA lung adenocarcinoma: a propensity score-matched analysis. Clin Lung Cancer. 2019;20(4):e504–13.
Metadaten
Titel
Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer
verfasst von
Taichi Matsubara, MD, PhD
Shinkichi Takamori, MD, PhD
Naoki Haratake, MD, PhD
Takatoshi Fujishita, MD, PhD
Ryo Toyozawa, MD
Kensaku Ito, MD, PhD
Mototsugu Shimokawa, MD, PhD
Masafumi Yamaguchi, MD, PhD
Takashi Seto, MD, PhD
Tatsuro Okamoto, MD, PhD
Publikationsdatum
21.10.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09230-x

Neu im Fachgebiet Chirurgie

Antibiotika bei Erwachsenen mit Appendizitis oft ausreichend

Bei etwa zwei Drittel aller Erwachsenen mit akuter Appendizitis könnte eine antibiotische Behandlung ausreichen, wie eine Metaanalyse nahelegt. Die Komplikationsrate war insgesamt gering, auch wenn letztlich doch eine Op. fällig wurde.

Katheterablation bei Vorhofflimmern: Ist frühe Intervention von Vorteil?

Bei Patienten mit Vorhofflimmern scheinen die Therapieergebnisse bezüglich Rezidivfreiheit bei frühzeitiger Katheterablation besser zu sein als bei später erfolgter Ablation. Dafür sprechen Ergebnisse einer aktuellen Registeranalyse. 

Beugt Tranexamsäure schweren Blutungen auch in der Allgemeinchirurgie vor?

Ergebnisse einer Subgruppenanalyse der POISE-3-Studie sprechen dafür, dass eine Prophylaxe mit Tranexamsäure auch bei allgemeinchirurgischen Eingriffen das Risiko für schwere Blutungen senkt.

Höhere Anspannung vor der Op. führt offenbar zu besserem Ergebnis

Ein gewisses Maß an Stress zu Beginn der Op. wirkt sich möglicherweise positiv auf das Gelingen aus, so ein Team aus Boston. Die Komplikationsrate ging unter diesen Umständen signifikant zurück.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.